AbCellera Biologics (ABCL) Operating Expenses (2020 - 2026)

AbCellera Biologics' Operating Expenses history runs 7 years deep, the most recent figure standing at $65.8 million for Q1 2026.

• Quarterly Operating Expenses fell 1.59% year-over-year to $65.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $291.2 million (down 15.76% YoY) and the FY2025 annual result came in at $292.2 million, down 14.95% from the prior year.
• Operating Expenses was $65.8 million for Q1 2026 at AbCellera Biologics, down from $73.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $100.8 million in Q2 2024 and bottomed at $54.3 million in Q2 2022.
• A 5-year average of $73.3 million and a median of $66.9 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 105.14% — and 2025, when it plunged 33.85%.
• AbCellera Biologics' Operating Expenses stood at $59.3 million in 2022, then increased by 26.82% to $75.2 million in 2023, then gained by 3.42% to $77.8 million in 2024, then decreased by 5.62% to $73.4 million in 2025, then declined by 10.35% to $65.8 million in 2026.
• Business Quant data shows ABCL's Operating Expenses at $65.8 million in Q1 2026, $73.4 million in Q4 2025, and $85.2 million in Q3 2025.